Answers are grounded in this paper and cite their sources.
Saudi Arabia has identified healthcare supply chain transformation as a key component of the Health Sector Transformation Program under Vision 2030, yet evidence on these reforms remains fragmented across sectors and policy domains. Drawing on the published literature, policy documents, institutional reports, and the authors’ experience in national procurement, regulation, and public health, this perspective examines four interacting components of transformation—procurement governance, digital infrastructure, local manufacturing capacity, and emergency preparedness—and applies this framework to antimicrobial resistance. Substantial reforms have been implemented, notably centralized procurement through the National Unified Procurement Company, national digital surveillance and traceability systems, and the localization of strategic medicines such as insulin. We propose that interactions among these reforms may influence supply chain resilience, although weak public–private data integration, dependence on imported active pharmaceutical ingredients, and limited performance evaluations prevent firm conclusions about their system-level effects. Remaining challenges include recurrent medicine shortages, regulatory bottlenecks, workforce gaps, and the limited availability of public performance indicators. The Saudi experience suggests that centralized, state-led reform should balance efficiency with redundancy, prioritize localization selectively, and build transparent performance monitoring into reforms from the outset.
No takes yet. Share an insight, caveat, or question.
Sheerah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: